New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
11:22 EDTCNQR, ARRY, FENG, JRCC, SBACHigh option volume stocks: SBAC FENG CNQR JRCC ARRY
News For SBAC;FENG;CNQR;JRCC;ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
07:03 EDTARRYArray BioPharma plans to submit binimetinib for marketing approval in 1H16
In December 2015, Array reported top-line results from the ongoing Phase 3 NEMO clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma. The study met its primary endpoint of improving progression-free survival compared with dacarbazine treatment, with a hazard ratio of 0.62, [95% CI 0.47-0.80] and a p-value of less than 0.001. The median PFS on the binimetinib arm was 2.8 months versus 1.5 months on the dacarbazine arm. In the trial, binimetinib was generally well-tolerated and the adverse events reported were consistent with previous results in NRAS melanoma patients. Array plans to submit binimetinib to regulatory authorities for marketing approval in NRAS-mutant melanoma during the first half of 2016. Results from the NEMO trial including progression free survival, overall survival, objective response rate, safety and prespecified subgroup analyses including outcomes in patients who received prior treatment with immunotherapy will be presented at a medical conference in 2016. In addition, Array expects top-line results from Part 1 of the COLUMBUS trial in the first half of 2016 and projects a regulatory filing of binimetinib and encorafenib in 2016. In October 2015, Part 2 of COLUMBUS achieved its target patient enrollment. The MILO Phase 3 study in patients with low-grade serous ovarian cancer continues to enroll patients, and Array estimates enrollment to be complete in 2016 with the availability of top-line data, along with a projected regulatory filing, in 2017. Based on the strength of the Phase 2 combination data with encorafenib in patients with BRAF-mutant colorectal cancer shared at the 2015 European Society of Medical Oncology's (ESMO) World Congress of Gastrointestinal Cancer, Array plans to initiate a Phase 3 global registration trial in that patient population in 2016.
07:03 EDTARRYArray BioPharma reports Q2 EPS (17c), consensus (6c)
Reports Q2 revenue $35.43M, consensus $32.7M.
February 1, 2016
11:57 EDTARRYDana-Farber, Array BioPharma to collaborate on immuno-oncology research
Dana-Farber Cancer Institute announced announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma. The research team at Dana-Farber's Robert and Renee Belfer Center for Applied Cancer Science will work with Array scientists on novel immune-oncology targets with the goal of bringing innovative medicines to patients. The collaboration will leverage the Belfer Center's proprietary immuno-oncology platform. Combining Dana Farber's oncology expertise with the Array's proficiency in drug discovery provides a unique opportunity to accelerate drug discovery of effective medicines for patients with unmet medical need.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use